Acipimox
Heart Diseases
National Heart, Lung, and Blood Institute (NHLBI)Small moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Heart Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
POTASSIUM Tufts Medical Center | Phase 3 | BB |
Orlistat University of British Columbia | Phase 4 | BB |
Acoramidis Eidos Therapeutics, a BridgeBio company | Phase 3 | BB |
WARFARIN Massachusetts General Hospital | Phase 3 | BB |
VITAMIN D | Phase 3 | BB |
View all 36 →
Same molecule, other indications
Acipimox is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →